BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

BACKGROUND: Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) are becoming a preferred treatment option. However, a considerable proportion of these carcinomas acquire resistance or harbour de novo resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, Goldie Y.L., Shaw, Reid, Schaub, Franz X., Stork, Isabella N., Gurley, Kay E., Bridgwater, Caroline, Diaz, Robert L., Rosati, Rachele, Swan, Hallie A., Ince, Tan A., Harding, Thomas C., Gadi, Vijayakrishna K., Goff, Barbara A., Kemp, Christopher J., Swisher, Elizabeth M., Grandori, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494677/
https://www.ncbi.nlm.nih.gov/pubmed/32927276
http://dx.doi.org/10.1016/j.ebiom.2020.102988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494677/
https://www.ncbi.nlm.nih.gov/pubmed/32927276
http://dx.doi.org/10.1016/j.ebiom.2020.102988

Ejemplares similares